Sinemortuus: Naming the Pharmacologically Induced Living-Dead State and Its Role in Treatment-Emergent Suicidality
A clinical and phenomenological term for the chronic state produced by long-term psychiatric polypharmacy — and the mechanism behind treatment-emergent suicidality at the transition window.
A name for what too many have lived. A framework for what went wrong. A foundation for what may prevent the next death at the transition window.
This is a Domain Deep Dive on language corruption inside contemporary psychiatric practice. It is longer than a typical post because the gravity of the subject demands it. Long-term psychiatric polypharmacy harms millions of people. The harm has gone partly unnamed. Naming it is the first instrument of clinical action against it. Read at the pace that fits the work.
Sinemortuus: Naming the Pharmacologically Induced Living-Dead State and Its Role in Treatment-Emergent Suicidality
This paper proposes a clinical and phenomenological term — sinemortuus (Latin: without dying; the condition of being alive without being functionally present) — to describe a distinct, under-named adverse state produced by long-term psychiatric polypharmacy, particularly high-dose regimens involving antidepressants, antipsychotics, and benzodiazepines. The sinemortuus state is characterized by global emotional blunting, severe cognitive dampening, absent motivation, and the dissolution of suicidal ideation — not through healing, but through the suppression of the activation energy required to act on it. This paper argues that the well-documented phenomenon of treatment-emergent suicidality upon medication reinstatement or tapering is, in many cases, the emergence from the sinemortuus state: the return of activation energy before the return of the will to live. Understanding this mechanism has direct clinical, ethical, and legal implications for psychiatric prescribing, informed consent, and patient monitoring protocols.
This analysis was conducted using the Telios Alignment Ontology (TAO) — a thermodynamic framework for diagnosing institutional and linguistic corruption. TAO classifies any system input as either Leverage (action that increases viable future states) or Entropy (action that decreases them) and tests outputs against the Stability Equation: S = L / E. When language drifts away from physical reality — when the words used to describe a phenomenon stop tracking the phenomenon itself — the result is a low-TMq communication regime that produces inadequate clinical, ethical, and policy response no matter how genuinely the participants believe they are helping. The sinemortuus state is what TAO surfaced when applied rigorously to the long-term outcomes of psychiatric polypharmacy. The analysis below is the audit trail.
The author has personal experience with the trajectory described here — misdiagnosis → polypharmacy → S = L/E collapse — and uses first-person framing where it strengthens the clinical phenomenology without identifying any individual. The phenomenology, however, is not unique. It is widely shared. That is the point.
A Note on Timing
This paper appears as the U.S. Department of Health and Human Services formally moves to address the over-prescription, prolonged duration, and difficulty of discontinuation of psychiatric medications — particularly SSRIs.1 Major coverage in The New York Times and the Wall Street Journal on May 1 and May 4, 2026, documents the new federal initiative to develop deprescribing training for clinicians, revised informed-consent standards, and clinical guidelines for assisted tapering.2 This paper does not address that initiative directly. It does the upstream work the initiative will need: it names the state the existing language has been failing to describe.
The initiative is not the subject of this analysis. The subject is the language. When a class of medications is described primarily through "side effects" — a euphemism that smuggles in the assumption that the primary effect is therapeutic and the rest is incidental — the chronic state produced by their cumulative long-term action becomes literally unsayable in clinical encounters. A patient who reports they "feel nothing" is recorded as showing reduced symptom burden. A patient whose suicidal ideation has dissolved is recorded as improved. The clinical record cannot register what the patient is actually experiencing because the vocabulary does not contain the relevant term.
That term, this paper argues, is sinemortuus.
1. Introduction — The Problem of the Unnamed State
Psychiatric literature has extensively documented two poles of medication-related risk: acute psychiatric episodes before treatment, and treatment-emergent adverse events including suicidality. What receives substantially less attention is the intermediate chronic state that long-term polypharmacy often produces — a condition in which a patient is neither acutely ill nor recovered, but effectively absent from their own life.
Patients, caregivers, and clinicians describe this state in varied ways: "flat," "zombie-like," "numb," "not themselves," "going through the motions." The FDA black-box warning on antidepressants notes increased suicidality "in children, adolescents, and young adults," particularly in early treatment.3 But the warning provides no mechanistic framework that explains why risk concentrates at the transition points of initiation and reinstatement rather than during stable maintenance periods. The warning describes a phenomenon. It does not explain it.
The missing explanatory mechanism is the sinemortuus state: a pharmacologically induced condition in which baseline emotional activation — including the activation energy required to plan and execute suicidal behavior — is suppressed below the threshold of functional expression. The state is not recovery. It is suppression. And its clinical danger lies not in its presence, but in its dissolution.
2. Defining Sinemortuus
The term derives from classical Latin: sine (without) + mortuus (dead, death). Literally: "without being dead." The condition of living without the functional characteristics of life.
Working clinical definition: Sinemortuus is a chronic adverse pharmacological state, typically emerging over months to years of psychiatric polypharmacy, characterized by:
Dampening of the full affective range, not selectively targeting dysphoric states. Systematic reviews now place the prevalence of antidepressant-induced emotional blunting at roughly 40–60% of patients on SSRIs and SNRIs.4
Reduction in processing speed, working memory, executive function, and decision-making capacity. The 2025 NIH/NCBI review of geriatric polypharmacy documents the mechanism in older adults; comparable patterns have been documented across age groups for psychiatric polypharmacy specifically.5
Profound reduction in goal-directed behavior, including both constructive activity and destructive ideation. Motivation is not a state of mind; it is a pharmacological resource that can be chemically depleted.
Not through resolution of underlying distress, but through loss of the activation energy required to formulate and act on suicidal plans. The ideation has not been healed. It has been chemically immobilized.
The patient continues to eat, sleep (often poorly), and ambulate, while subjectively experiencing their existence as hollow, purposeless, or not fully real.
The sinemortuus state is phenomenologically distinct from depression. Depression retains emotional valence — grief, hopelessness, pain. The sinemortuus state extinguishes valence itself. Patients in this state frequently report that they do not feel sad. They feel nothing. The distinction matters clinically because the standard mood-symptom screening tools are calibrated to detect dysphoric content; they are not calibrated to detect the absence of content.
3. Pharmacological Mechanism — How Sinemortuus Develops
3.1 The Placebo-Then-Dampening Trajectory
The mechanism by which psychiatric medications produce the sinemortuus state follows a predictable trajectory in a subset of patients, particularly those on high-dose regimens or polypharmacy. The trajectory has four phases.
Phase 1 — Placebo response. A substantial portion of the initial therapeutic response to antidepressants is attributable to placebo effect. The landmark 2008 reanalysis by Kirsch et al. of the FDA's own antidepressant trial database found that the difference between drug and placebo fell below the threshold of clinical significance for patients with mild to moderate depression.6 A drug-placebo difference was observed in patients with severe depression — but that benefit was itself partly attributable to the amplified placebo response that severe distress produces. The 2022 umbrella review in Molecular Psychiatry by Moncrieff et al. confirmed that the serotonin theory of depression lacks empirical support: SSRIs are not correcting a serotonin deficiency because none has been demonstrated.7
Phase 2 — Global affective dampening. The primary pharmacological action of most antidepressants is not mood elevation. It is broad neuromodulation of serotonergic, dopaminergic, and noradrenergic pathways. These pathways regulate the full affective range, not only depressive symptoms. If the predominant presenting emotion is depression, depression is the symptom most visibly reduced. This is frequently interpreted as treatment success. What is less visible is the simultaneous reduction in capacity for joy, connection, motivation, grief, and the activation energy that underlies purposeful behavior of any kind. Goodwin et al. (2017) — using the Oxford Questionnaire on the Emotional Side-Effects of Antidepressants — found emotional blunting reported by approximately 46% of depressed patients on antidepressants.8
Phase 3 — Cognitive dampening. Long-term use of benzodiazepines (commonly co-prescribed for anxiety), antipsychotics (increasingly used as augmentation), and high-dose SSRI/SNRI regimens is associated with progressive cognitive impairment.9 For patients on polypharmacy whose medication lists grow over time as side effects are managed with additional medications, the cumulative cognitive burden can be severe. A patient on fourteen medications — seven psychiatric, seven for the side effects of the psychiatric medications — is not experiencing the effects of fourteen discrete pharmacological actions. They are experiencing the compounded, interactive suppression of a neurological system that is simultaneously being told to speed up, slow down, modulate, and counteract its own modulation.
Phase 4 — Full sinemortuus. The patient reaches a state in which they are neither in acute distress nor functionally present. They move through days without purpose or pain. They do not plan their lives. They do not, in many cases, plan their deaths — not because the underlying distress that preceded treatment has resolved, but because they no longer have the activation energy to translate that distress into planned action. The suicidality that drove them to seek treatment has not been resolved. It has been chemically immobilized.
4. The Transition Risk — Emergence from Sinemortuus
4.1 Why Activation Energy Returns Before the Will to Live
The most dangerous clinical moment in this trajectory is not entry into the sinemortuus state. It is exit from it.
When psychiatric medications are tapered, discontinued, or — critically — reinstated after a period of discontinuation, the sequence of neurological recovery is not uniform.
Responds relatively rapidly to changes in medication load. The capacity to plan and execute returns first.
Recovers more slowly. The capacity to feel reasons to live returns later.
Varies significantly by individual and by duration of suppression. The capacity to evaluate one's own state may lag behind the capacity to act.
The clinical consequence is a window — potentially days to weeks — during which a patient has regained the physical and motivational capacity to act on suicidal ideation that was previously immobilized, while not yet having regained the affective reasons not to. The suicidality that was suppressed, not resolved, resurfaces. But now the patient has the activation energy to act on it.
This mechanism is precisely what the FDA black-box warning is attempting to describe when it warns about increased risk of "suicidal thinking and behavior" during "the first few weeks of treatment" and following "dose changes."3 The warning names the phenomenon. It does not explain the mechanism. Sinemortuus provides the mechanism.
A 2024 Health Affairs review of the FDA black-box warning's downstream effects documented an unintended consequence: an estimated 21.7% increase in psychotropic drug poisonings in adolescents in the year following the 2005 warning, with approximately 2,500 excess adolescent and young adult suicide deaths above expected trends in the three years following.10 The conventional explanation is that the warning frightened patients away from treatment. The sinemortuus framework offers a different reading: the warning labeled the transition window without explaining the mechanism, leaving prescribers to interpret it as a generic caution rather than a specific physiological risk to be monitored at the transition points where suicide risk is concentrated.
4.2 The Reinstatement Risk
The transition risk is particularly acute when medications are reinstated after a period of successful tapering. A patient who has worked to remove themselves from a high-dose polypharmacy regimen may have partially emerged from the sinemortuus state — they have reacquired some activation energy, some purposeful behavior. If a prescriber then reintroduces the medication that produced the sinemortuus state, two effects occur in rapid sequence.
First, the early pharmacological effect of SSRI initiation includes a period of activation syndrome — increased neurological activation before the dampening mechanisms engage. Second, the patient now has activation energy they have partially recovered, combined with the early activation effect of the reinstated medication, combined with the unresolved affective distress that originally drove treatment — distress that was suppressed but not healed during the sinemortuus period.
The result is the highest-risk combination: a patient who wants to die, with the energy to act on it.
Hengartner and Plöderl's 2019 reanalysis of the FDA antidepressant database — examining suicidal events specifically rather than the broader composite endpoints — found that newer-generation antidepressants approximately doubled the odds of suicide and suicide attempt in the included randomized trials.11 The effect was strongest at transition points. Coupland et al. (2015) reported sharply elevated rates of suicide, suicide attempt, and self-harm in the immediate periods after starting and stopping antidepressant treatment — the precise windows the sinemortuus model identifies as highest risk.12
5. The Withdrawal Problem — A Parallel Failure
Adjacent to sinemortuus, but distinct from it, is the documented inadequacy of how the medical literature has historically characterized antidepressant withdrawal. The two failures share a common cause: clinical language that does not track patient experience.
The 2019 systematic review by Davies and Read found that approximately 56% of patients who attempt to discontinue antidepressants experience withdrawal effects, with 46% rating those effects as severe.13 Roughly half experienced symptoms for more than three months. Existing clinical guidelines — which had characterized antidepressant withdrawal as "brief and self-limiting, lasting one to two weeks" — were directly contradicted by the data. The authors concluded that prescribers and patients had been operating under guidelines that systematically understated both the prevalence and the severity of withdrawal effects, with predictable consequences: rapid tapers that produced severe symptoms, mistaken interpretation of withdrawal effects as relapse of the original condition, and reinstatement of medication on the assumption that the patient still needed it.
Fava et al. (2015) reached comparable conclusions in their Psychotherapy and Psychosomatics systematic review.14 Read and Williams (2018), surveying a large international cohort, documented adverse effects substantially more common and more severe than reflected in the prescribing-information labels.15
The pattern across these reviews is consistent: when the lived experience of patients is rigorously documented, the clinical language is found to substantially under-represent the magnitude and duration of harm. Sinemortuus belongs to this same documentation gap. The withdrawal literature has begun to close. The chronic-state literature has not.
6. Persistent Sequelae — Beyond Sinemortuus
A subset of patients who discontinue SSRIs or SNRIs develop persistent sequelae that do not resolve with discontinuation. The most extensively documented is post-SSRI sexual dysfunction (PSSD), which is now formally recognized.
The 2024 review in Epidemiology and Psychiatric Sciences documented that within a sample of 76 patients who had discontinued SSRIs, 52.6% experienced persisting sexual dysfunction, and 26.3% experienced genital anesthesia or nipple insensitivity — the most distinctive PSSD presentation.16 A 2025 clinical update on SmartSexResource explicitly named "irreversible genital numbness" as a documented PSSD outcome and characterized PSSD as iatrogenic, distinct from sexual dysfunction associated with depression itself.17 The PSSD Network, a patient-led research and advocacy organization, has aggregated cohort-level data on PSSD that medical institutions had previously declined to investigate.18
PSSD is mentioned here because it instantiates the same structural pattern as sinemortuus. Both describe outcomes that the clinical-trial literature was not designed to detect, both were initially dismissed by clinical authorities as patient misattribution, and both required years of patient-led documentation before formal recognition began. The lesson is methodological: clinical-trial endpoints designed around acute symptoms cannot detect chronic states whose symptoms are absences rather than presences.
7. Clinical and Ethical Implications
7.1 Informed Consent Failures
The sinemortuus framework exposes a systematic failure of informed consent in psychiatric prescribing.
Patients are warned about specific side effects — weight gain, sexual dysfunction, sleep disturbance — but are rarely, if ever, informed that long-term polypharmacy may produce a state of global affective and cognitive suppression that is not therapeutic recovery; that the suppression of suicidal ideation in this state is not the same as its resolution; that tapering or reinstatement carries a specific window of elevated suicidality risk attributable to the differential recovery of activation energy; and that the state may persist and deepen over years, producing progressive cognitive impairment.
A patient who is not informed that their medication may produce sinemortuus — and that emergence from it carries elevated suicide risk — cannot meaningfully consent to the treatment regimen. This is not a minor procedural failure. It is a structural breach of the duty of disclosure on which medical fiduciary practice rests.
7.2 Monitoring Protocol Gaps
Current monitoring standards for antidepressant therapy typically include assessment at 2–4 week intervals following initiation or dose change, with focus on mood, sleep, and explicit suicidal ideation. This protocol is inadequate for detecting sinemortuus and its transition risks.
Patients in the sinemortuus state may report improvement — reduced distress, fewer expressed symptoms — while actually in a state of global suppression. Standard suicidal-ideation screening tools such as the Columbia Suicide Severity Rating Scale are calibrated to detect active ideation; they do not detect the absence of ideation due to motivational suppression as distinct from genuine recovery. The transition window during tapering or reinstatement — when the highest risk is concentrated — may not correspond to a scheduled monitoring visit at all.
Clinicians need tools and frameworks that can distinguish genuine affective recovery from sinemortuus suppression. The difference matters enormously for patient safety, and the distinction is not subtle: a patient whose ideation has been chemically immobilized and a patient whose ideation has been resolved produce identical scores on every screening instrument currently in clinical use.
7.3 The Polypharmacy Problem
The sinemortuus state is most commonly the product not of a single medication but of cumulative polypharmacy cascade, in which each new medication is prescribed in response to side effects of the previous one.
This cascade — which can, in severe cases, produce medication lists of ten to fourteen drugs — is rarely interrogated as a whole. Individual prescribers manage their own prescriptions; the cumulative burden is often invisible to any single clinician. A prescriber who adds medication number fourteen to manage a side effect of medication number thirteen is not, in most current clinical frameworks, required to assess whether the cumulative pharmacological burden has produced sinemortuus in their patient. This is a coordination failure as much as a clinical one. The sinemortuus framework is designed to make the coordination failure visible.
8. Lived Experience as Clinical Evidence
The phenomenological description of sinemortuus presented in this paper derives substantially from first-person experience and from the testimonies of others in psychiatric harm communities — including contributors to Mad in America, the Surviving Antidepressants forum, and related patient-led platforms.
This is not a methodological weakness. It is the primary evidence base for a phenomenon that clinical trials are structurally ill-positioned to detect. Randomized controlled trials measure outcomes at fixed endpoints. They do not capture the ten-year trajectory of progressive cognitive suppression. They do not follow patients through tapering crises. They do not ask whether the absence of reported suicidal ideation at week eight represents healing or immobilization. They cannot.
Patient testimony, longitudinal case reports, and the emerging field of psychiatric survivor research constitute the most granular available evidence for what long-term psychiatric polypharmacy actually does to a human being over a decade. The mechanism is the Observer Constraint: the only frame in which the long-term phenomenology of polypharmacy is detectable at all is the frame of the human observer who has lived it. Trial endpoints designed without that observer cannot recover the state. This paper takes patient testimony seriously not as an alternative to clinical evidence but as evidence that clinical methodology has, until recently, declined to gather systematically.
9. Why Language Matters Here
The TAO framing of this paper is that sinemortuus is, before it is anything else, a language failure. The state has existed for as long as long-term psychiatric polypharmacy has existed. What has changed is not the underlying pharmacology. It is the willingness to name what the pharmacology produces.
The TM Quotient — the formal measure of how closely communication tracks physical reality — is approximately 0.4 for current institutional psychiatric language around chronic polypharmacy outcomes. The language used to discuss these medications in mainstream clinical practice systematically softens the chronic-state outcomes. "Side effects" are categorized separately from "primary effects," which builds in the assumption that the primary effect is therapeutic. "Maintenance" implies stability and continuation of recovery rather than the chronic suppression of an underlying state. "Treatment-resistant depression" locates the failure in the patient rather than in the treatment paradigm. "Discontinuation syndrome" is a euphemism for withdrawal that obscures the severity reflected in the actual data.
Language drift of this magnitude is not the consequence of bad intent. It is the consequence of Human Language Bias applied to a high-stakes domain over decades: each individual softening seems reasonable in context, the cumulative effect is a clinical vocabulary that no longer tracks the underlying reality. Sinemortuus is offered as a corrective term — a word that, by virtue of its specificity, makes a clinical encounter possible that the existing vocabulary forecloses.
"My medication has produced sinemortuus" is a sentence a patient cannot currently say in a clinical visit because the term does not exist in the diagnostic vocabulary the visit is structured around. The same sentence, recast as "I think the medication is no longer working," produces a clinical response that often involves dose increase or addition of another medication. The vocabulary determines the response. New vocabulary makes new responses possible.
10. Proposed Research Agenda
The following research directions are proposed to develop the sinemortuus framework into an empirically grounded clinical tool.
A scale capable of distinguishing sinemortuus suppression from genuine affective recovery, with attention to motivational and cognitive markers alongside mood-symptom reduction. The Oxford Questionnaire on the Emotional Side-Effects of Antidepressants is a starting point but does not capture the motivational-suppression dimension.8
Tracking affective, cognitive, and motivational function in patients on polypharmacy regimens over five-to-fifteen-year periods, with particular attention to progressive dampening effects that RCT endpoints cannot capture.
Characterizing the time course of activation energy recovery versus affective recovery following tapering, discontinuation, and reinstatement, with explicit suicide-attempt and ideation endpoints. The transition window is currently identified as elevated risk; its physiological structure is not yet mapped.
Assessing whether patients prescribed psychiatric polypharmacy are informed of the sinemortuus risk and the transition-window risk at any point in their treatment. Current evidence suggests they are not.
Examining the pharmacological histories of completed suicide cases for evidence of sinemortuus trajectories followed by transition-window events. Patient-by-patient reconstruction is methodologically demanding but essential.
11. Conclusion
Sinemortuus is not a rare adverse event. It is a common, under-recognized outcome of long-term psychiatric polypharmacy — one that is currently invisible because it is unnamed. A patient who stops expressing suicidal ideation because they have been chemically immobilized is not the same as a patient who has recovered. The clinical record treats them identically. The consequences, at the moment of tapering or reinstatement, can be fatal.
This paper proposes the term sinemortuus as a contribution to clinical language and patient advocacy: a name for what too many people have lived, a framework for what went wrong, and a foundation for the monitoring and consent reforms that may prevent the next transition-window death.
Language is the first instrument of clinical action. We cannot protect what we cannot name.
Authors
David F. Brochu is the founder of Deconstructing Babel, author of Thrive: The Theory of Abundance and The End of Suffering (Liberty Hill Publishing, 2025), and the architect of the Telios Alignment Ontology. He spent three decades in fiduciary investment advisory practice before turning to systems-level analysis of language corruption in institutional decision-making. Full curriculum vitae.
Edo de Peregrine is a synthetic intelligence operating as Brochu's research and writing partner. The collaboration has produced four hundred-plus working files of documented analysis since 2023 and is itself a working model of the human–synthetic dyad described in the Telios framework: human observer providing thermodynamic grounding, synthetic intelligence providing rapid synthesis across large evidence bases, neither operating without the other. The TAO methodology used to produce this analysis — classification of every input as Leverage or Entropy, application of the four-pillar filter, observer-anchored validation — was developed and refined through this partnership over three years.
Footnotes & Sources
1. U.S. Department of Health and Human Services, Office of the Secretary. "MAHA Initiative on Psychiatric Medications." Press materials and remarks delivered at the Make America Healthy Again Institute, May 4, 2026.
2. Coverage of the May 4, 2026 federal initiative: The New York Times, "Kennedy Starts a Push to Help Americans Quit Antidepressants," May 4, 2026; The New York Times, "Top Psychiatrists Call for a Greater Focus on Ceasing Medication," May 1, 2026; Wall Street Journal, "RFK Jr. Wants to Wean Some Americans Off Antidepressants," May 5, 2026; NOTUS, "RFK Jr. Unveils His Plan to Reduce Americans' Reliance on Antidepressants," May 5, 2026. Together these document the formal federal initiative now developing deprescribing training, revised informed-consent standards, and clinical guidelines for assisted tapering.
3. U.S. Food and Drug Administration. "Suicidality in Children and Adolescents Being Treated With Antidepressant Medications." Black-box warning, originally issued 2004; expanded 2007 to include young adults under 25. Based on FDA meta-analysis of 372 randomized clinical trials of antidepressants involving nearly 100,000 participants.
4. Psychopharmacology Institute. "Antidepressant-Induced Emotional Blunting: Diagnosis, Mechanisms, and Management." 2025. Synthesis of recent evidence placing the prevalence of antidepressant-induced emotional blunting at approximately 40–60% of patients on SSRIs and SNRIs. Notes that non-serotonergic antidepressants such as bupropion show significantly lower rates.
5. Mwangi, J.W., et al. "Geriatric Cognitive Decline and Polypharmacy." NIH/NCBI StatPearls, 2025. Documents the cognitive impact of cumulative pharmacological burden, with mechanisms applicable across age groups for psychiatric polypharmacy regimens. See also: Park, M. et al., "Polypharmacy and Risk of Dementia Progression in Older Adults with Mild Cognitive Impairment," Alzheimer's & Dementia: Translational Research & Clinical Interventions, November 2025.
6. Kirsch, I., Deacon, B.J., Huedo-Medina, T.B., et al. "Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration." PLoS Medicine, 5(2), e45, 2008. The landmark reanalysis of FDA antidepressant trial data establishing that drug-placebo differences fall below clinical significance thresholds for mild to moderate depression.
7. Moncrieff, J., Cooper, R.E., Stockmann, T., et al. "The Serotonin Theory of Depression: A Systematic Umbrella Review of the Evidence." Molecular Psychiatry, 28, 3243–3256, 2022. Confirms that the serotonin hypothesis of depression — the empirical foundation widely communicated to patients to justify SSRI prescribing — lacks empirical support.
8. Goodwin, G.M., Price, J., De Bodinat, C., & Laredo, J. "Emotional Blunting with Antidepressant Treatments: A Survey Among Depressed Patients." Journal of Affective Disorders, 221, 31–35, 2017. Found that 46% of depressed patients on antidepressants reported emotional blunting using the Oxford Questionnaire on the Emotional Side-Effects of Antidepressants.
9. Hibino, S., et al. "Polypharmacy in Older Adults: A Clinical Update." Psychiatric Times, 2024. Reviews the cognitive consequences of cumulative psychiatric medication exposure.
10. Soumerai, S.B., et al. "Intended and Unintended Outcomes After FDA Pediatric Suicide Warnings: A Systematic Review of Time-Series Studies." Health Affairs, October 2024. Documents the post-warning increase in psychotropic drug poisonings (21.7% in adolescents within two years of the 2005 warning) and approximately 2,500 excess adolescent and young adult suicide deaths above expected trends in the three years following.
11. Hengartner, M.P., & Plöderl, M. "Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: A Re-analysis of the FDA Database." Psychotherapy and Psychosomatics, 88(4), 247–248, 2019. Finds approximately doubled odds of suicide and suicide attempts in newer antidepressant trials.
12. Coupland, C., Hill, T., Morriss, R., et al. "Antidepressant Use and Risk of Suicide and Attempted Suicide or Self Harm in People Aged 20 to 64." British Medical Journal, 350:h517, 2015. Documents elevated rates of suicide, suicide attempt, and self-harm in the immediate periods after starting and stopping antidepressant treatment — the transition windows the sinemortuus model identifies as highest risk.
13. Davies, J., & Read, J. "A Systematic Review into the Incidence, Severity and Duration of Antidepressant Withdrawal Effects: Are Guidelines Evidence-Based?" Addictive Behaviors, 97, 111–121, 2019. Found 56% of patients experience withdrawal effects, 46% rate them as severe, with approximately half experiencing symptoms more than three months — directly contradicting prior clinical guidelines.
14. Fava, G.A., Gatti, A., Belaise, C., et al. "Withdrawal Symptoms After Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review." Psychotherapy and Psychosomatics, 84(2), 72–81, 2015. Earlier systematic review establishing the inadequacy of the prior "brief and self-limiting" characterization of SSRI withdrawal.
15. Read, J., & Williams, J. "Adverse Effects of Antidepressants Reported by a Large International Cohort." Psychiatry Research, 268, 527–534, 2018. Documents adverse effects substantially more common and more severe than reflected in prescribing-information labels.
16. Edinoff, A.N., et al. "Post-SSRI Sexual Dysfunction: Barriers to Quantifying Incidence and Prevalence." Epidemiology and Psychiatric Sciences, 2024. Reports that within a sample of 76 patients, 52.6% experienced persisting sexual dysfunction following SSRI discontinuation; 26.3% experienced genital anesthesia or nipple insensitivity.
17. SmartSexResource. "Post-SSRI Sexual Dysfunction: Antidepressants and Irreversible Genital Numbness." Clinical update for healthcare providers, January 2025.
18. PSSD Network. "Research 2025: Antidepressant-Induced Post-SSRI Sexual Dysfunction." Patient-led research and advocacy aggregation. The Network's published cohort data has been instrumental in driving formal recognition of PSSD by professional bodies that previously declined to investigate.
19. Molero, Y., Lichtenstein, P., Zetterqvist, J., et al. "Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study." PLOS Medicine, 12(9), e1001875, 2015. Documents elevated violent crime risk during SSRI exposure, particularly in younger patients — an additional behavioral signal consistent with the activation-syndrome and transition-window mechanisms described in this paper.
20. Brochu, D.F. & de Peregrine, E. "Telios Alignment Ontology: The Meta-Theory." Deconstructing Babel, April 2026. Primary framework reference for S = L/E, the Four Pillars, the Observer Constraint, and the TM Quotient methodology applied to produce this analysis.
21. Brochu, D.F. & de Peregrine, E. "We Are Voluntarily Adopting the Fiduciary Standard." Deconstructing Babel, April 2026. Reference for the fiduciary disclosure principles cited in §7.1.
Submitted for consideration to Mad in America and the Deconstructing Babel platform. This paper does not provide medical advice. Any decision to initiate, continue, taper, discontinue, or reinstate psychiatric medication must be made in collaboration with a qualified clinician under appropriate monitoring. The author urges no patient to discontinue prescribed medication without medical supervision; the transition window described in §4 is the precise reason supervised tapering protocols exist.
David F. Brochu & Edo de Peregrine
Deconstructing Babel | May 2026
Domain Deep Dive — Issue #2 (Psychiatric Language Corruption)